Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Micro-Cap Pharma Moving Ahead with Plans for Phase 3 US Trial of a Repurposed Drug for Covid-19

Revive Therapeutics is focused on infectious diseases as well as treatments using psilocybin-based formulations. Revive Therapeutics Ltd. (RVV:TSX.V; RVVTF:OTCMKTS) , a company that focuses on repurposing drugs for infectious diseases and rare disorders, is prepari...
Streetwise Reports | June 4, 2020 |

Small-Cap Pharma Fast-Tracking Repurposed Drug for Covid-19

Algernon Pharmaceuticals is quickly moving ahead with a multinational Phase 2b/3 trial for Ifenprodil. Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE) , a Canada-based clinical stage drug development company that focuses on drug repurposing, believes ...
Streetwise Reports | May 28, 2020 |

Flying Under the Radar with a Possible COVID-19 Treatment

Investors would think a pharmaceutical company heading into Phase 2b/3 human trials for treating the third most malignant disease after lung cancer and pancreatic cancer would draw eyes from major players. If that same company announced it was embarking on Phase2b/3 human tri...
Stockhouse Editorial | September 8, 2020 |

Biopharma's Technology Could Render Drug Suitable for COVID-19 Treatment

How this could be achieved using the proprietary platform of TFF Pharmaceuticals and why it could work are discussed in a ROTH Capital Partners report. In an April 7 research note, ROTH Capital Partners analyst Jonathan Aschoff discussed the potential of app...
Streetwise Reports | April 9, 2020 |

Buzz on the Bullboards: Whose stocks sizzle during summer holidays?

As we get through the summer holiday season, the typically calmer market environment presents a prime opportunity for investors to evaluate their portfolios and consider new investments. The TSX continues to offer a variety of promising stocks, particularly in energ...
Jonathon Brown | July 4, 2024 |

XPhyto: The Cutting Edge of Medical Cannabis Science

At the forefront of the next wave of cannabis commercialization, is a German-focused company with headquarters in Vancouver, XPhyto Therapeutics Corp. (CSE: XPHY; FSE: 4XT) , that is building a much-coveted cannabis R&D cultivation facility in a converted nuclear bunker and o...
Marc Davis | November 12, 2019 |

Biopharma Co. Makes Major Headway Toward Clinical Trials for Treatment of Stroke

(CLICK IMAGE TO PLAY VIDEO) Finding an effective method of preventing the possibility of stroke is something that medical science has grappled with for decades. Now, a Vancouver-based clinical stage biopharmaceutical development company looks to be making significa...
Dave Jackson | June 16, 2021 |

Ibogaine Drug Development: Creating The Gold Standard For Addiction Treatment

(Click image to play video.) A renewed interest in the therapeutic power psychedelic of compounds is revealing a potent and commercially viable solution. Vancouver BC-based Universal Ibogaine Inc. (UI) ( TSX-V: IBO , Forum ) is positioned to address the opioid e...
Dave Jackson | October 26, 2021 |

A Key Investment Strategy into Monetizing and Host Webinars

Investors with a keen eye to the live video conferencing technology boom, should look at the entire space beyond Zoom. Enter Personas Social Inc. ( TSX-V.PRSN , OTCMKTS: PRSNF , Forum ) – a unique company engaged in the business of offering live video conferencing ...
Dave Jackson | March 4, 2022 |